Research Topics
Genomes and Genes | Anne Genevieve MarcelinSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimensA G Marcelin
Universite Pierre et Marie Curie Paris 6, UMR S 943, Paris F 75013, France
J Antimicrob Chemother 67:1475-8. 2012....
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimenAnne Genevieve Marcelin
AP HP, Pitie Salpetriere Hospital, Pierre et Marie Curie University, INSERM U943, Paris, France
Antivir Ther 17:119-23. 2012..The aim of this study was to characterize the mutations selected upon failure on etravirine (ETR)-containing regimen in non-nucleoside reverse transcriptase inhibitors (NNRTIs)-experienced HIV-infected patients and the associated factors...
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 54:72-7. 2010..In conclusion, ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used...
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 52:3237-43. 2008....
[HIV drug resistance]Anne Genevieve Marcelin
Service de Virologie, Hopital de la Pitie, 75651 Paris Cedex 13
Rev Prat 56:978-86. 2006..These tests are now widely used in developed countries and are recommended in case of therapeutic failure in treated patients and in case of recent infection in naive patients...
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trialsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 52:4251-7. 2008....
[Resistance to protease inhibitors: the burden of mutations]A G Marcelin
Service de Virologie, , 47, , 75013 Paris, France
Med Mal Infect 36:S198-205. 2006
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpftriere Hospital, AP HP, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 12:247-52. 2007..To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients...
Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated diseaseAnne Genevieve Marcelin
Service de virologie UPRES EA 2387, Paris, France
J Infect Dis 196:1163-6. 2007..63 log(10) copies/150,000 cells). Determining the KSHV-DNA level may be useful in diagnosing KSHV-associated disease and for following up patients with KS when the development of MCD or PEL is suspected...
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasmaAnne Genevieve Marcelin
UPMC Univ Paris 06, EA 2387, Paris, France
AIDS 22:1677-9. 2008..This result justifies measuring HIV-1 RNA in semen before the ART process and suggests that a residual risk of transmission has to be mentioned to the patients who would like to have unprotected sexual intercourse...
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patientsDiane Descamps
AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
J Antimicrob Chemother 63:585-92. 2009..The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens...
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureAnne Genevieve Marcelin
Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
J Med Virol 72:162-5. 2004....
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)Constance Delaugerre
Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
J Med Virol 77:345-50. 2005..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen...
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
J Med Virol 74:16-20. 2004..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection...
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological surveyConstance Delaugerre
Department of Virology EA3620, Necker Hospital, Paris, France
AIDS 21:1365-7. 2007..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed...
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirSidonie Lambert-Niclot
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris 75013, France
Antimicrob Agents Chemother 52:491-6. 2008..TPV susceptibility does not seem to be affected by the selection of a DRV resistance mutation...
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
Antimicrob Agents Chemother 47:594-600. 2003....
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trialVincent Calvez
Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
Antivir Ther 7:211-8. 2002....
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, MaliAnne Derache
Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 12:123-9. 2007..To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance in treatment-naive, HIV-1-infected individuals living in Mali...
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet
Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
Antimicrob Agents Chemother 52:1351-8. 2008..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrasesIsabelle Malet
UPMC Universite Paris 06, Paris, France
J Med Virol 80:754-61. 2008..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials...
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patientsIsabelle Malet
Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
J Infect 54:367-74. 2007..Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI)...
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemiaMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, 83 bvd de l Hôpital, 75013 Paris, France
J Antimicrob Chemother 66:709-12. 2011..Analyses of proviral HIV-DNA can provide information about the viral reservoir, because integrated DNA reflects both actively and latently infected cells...
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individualsClaudine Duvivier
Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 8:603-9. 2003..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients...
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
Antimicrob Agents Chemother 48:4687-92. 2004....
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapySidonie Lambert-Niclot
AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
J Antimicrob Chemother 67:1470-4. 2012....
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulie
Universite Pierre et Marie Curie Paris 6, UMR S 943 Paris, F 75013, France
J Antimicrob Chemother 65:749-51. 2010..We aimed to analyse HIV-1 tropism using proviral DNA sequencing and the associated factors, in a group of patients on antiretroviral (ARV) treatment with an undetectable viral load in plasma...
Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trialJean Michel Molina
Department of Infectious Diseases, Saint Louis Hospital, Paris, France
J Infect Dis 191:840-7. 2005..The antiviral efficacy of didanosine in patients experiencing virological failure is not well known...
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAARTCathia Soulie
Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
AIDS 21:2243-5. 2007..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART...
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drugMarc Wirden
Department of Virology, AP HP, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
J Antimicrob Chemother 64:1087-90. 2009..We determined whether raltegravir retains residual antiretroviral activity in vivo against viruses harbouring raltegravir mutations, and thus whether the drug can contribute to the subsequent regimen...
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypesAlmoustapha Issiaka Maiga
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
Antimicrob Agents Chemother 54:728-33. 2010..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility...
Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosineAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 11:693-9. 2006..To determine the potential impact of reverse transcriptase (RT) mutations, other than those currently known to confer nucleoside reverse transcriptase inhibitors (NRTIs) resistance, on the virological response to didanosine (ddl)...
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden
Department of Virology, , Bichat Hospital, Paris, France
J Clin Microbiol 41:2713-5. 2003..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patientsMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, 75013 Paris, France
Antimicrob Agents Chemother 50:2553-6. 2006..L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz...
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitorsBenedicte Roquebert
Department of Virology, Pitie Salpetriere Hospital, Paris, France
AIDS 20:287-9. 2006..These minor species, not detected by standard genotype, may influence PI susceptibility...
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patientsMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, Paris, France
J Med Virol 76:297-301. 2005..The K65R mutation can emerge even with TAMs or L74V. No obvious impact was shown on the TAMs or other NRTI mutations, although a trend towards emergence of some particular mutations was observed...
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtideDiane Descamps
AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
J Antimicrob Chemother 62:451-5. 2008..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performanceDiane Descamps
Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
J Med Virol 78:153-60. 2006..077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments...
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsFabienne Caby
Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
Scand J Infect Dis 42:527-32. 2010..If persistent low viraemia is observed over more than 48 weeks without the emergence of resistance, RAL should never be given as functional monotherapy, as it is associated with a maximal risk of VF and the emergence of RAL resistance...
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeksSidonie Lambert-Niclot
AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
PLoS ONE 7:e41390. 2012..Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study...
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtypeIsabelle Malet
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
J Antimicrob Chemother 66:2827-30. 2011..The aim of this study was to explore resistance pathways preferably used by CRF02_AG viruses compared with subtype B...
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patientsBenedicte Roquebert
Department of Virology, Pitié Salpêtrière Hospital and UPRES EA 2387, Universite Pierre et Marie Curie, Paris, France
J Med Virol 79:207-11. 2007..Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance...
Clinically relevant genotype interpretation of resistance to didanosineAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 49:1739-44. 2005..In conclusion, we developed and validated a genotypic score, taking into account mutations negatively and positively impacting the virologic response to ddI...
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot
UPMC Univ Paris 06, EA 2387, F 75005, Paris, France
J Antimicrob Chemother 62:905-8. 2008..To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations...
HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitisCathia Soulie
Universite Pierre et Marie Curie Paris 6, UMR S 943, France
AIDS 24:2412-4. 2010..Conversely, a high viral genetic diversity was associated with an undetectable HIV RNA in plasma and low-balanced CPE, which is in favour of an autonomous replication in the central nervous system...
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nCathia Soulie
Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
AIDS 23:1605-8. 2009..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapySidonie Lambert-Niclot
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
Antimicrob Agents Chemother 54:4910-3. 2010..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden
Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
Antimicrob Agents Chemother 48:644-7. 2004....
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trialChristophe Piketty
Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
Antivir Ther 11:213-21. 2006..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapySidonie Lambert-Niclot
Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
J Infect Dis 204:1211-6. 2011..Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy...
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
J Antimicrob Chemother 66:1481-3. 2011....
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypesAlmoustapha Issiaka Maiga
Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 14:123-9. 2009..The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF02_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries...
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposureSlim Fourati
Université Pierre et Marie Curie Paris, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris, France
AIDS 26:1619-24. 2012..We show here that APOBEC3 proteins play a role in the emergence of these drug resistance mutations...
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practiceSidonie Lambert-Niclot
AP HP, Pitie Salpetriere Hospital, INSERM U943 and Pierre et Marie Curie University, Paris, France
J Antimicrob Chemother 67:2487-93. 2012..Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients...
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
J Antimicrob Chemother 67:2494-500. 2012..To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143...
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimenAnne Genevieve Marcelin
Pitie Salpetriere Hospital, Paris, France
AIDS 21:2341-3. 2007..This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options...
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patientsIsabelle Malet
Laboratoire de Virologie, Universite Pierre et Marie Curie Paris 6, France
AIDS 21:871-3. 2007..Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo...
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutationsSlim Fourati
Universite Pierre et Marie Curie, Paris, France
Antiviral Res 93:167-74. 2012..This process may play a role in the kinetics of appearance of drug resistance mutations under antiretroviral treatment...
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsIsabelle Malet
UPMC Univ Paris 06, F 75005 Paris, France
J Antimicrob Chemother 63:795-804. 2009..The objective of this study was to characterize the dynamics of HIV-1 quasispecies variant populations in patients who failed to respond to raltegravir treatment...
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancyJade Ghosn
AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
Antimicrob Agents Chemother 52:1542-4. 2008..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV...
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patientsMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, Paris, France
AIDS 23:95-9. 2009..This lack of knowledge has led to contradictory and confusing attitudes to L74I; although this mutation is not listed by the International AIDS Society - USA, it is increasingly included in several resistance algorithms...
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006Anne Derache
UPMC Univ Paris 06, EA2387, 4 place Jussieu, F 75005 Paris, France
J Antimicrob Chemother 62:456-63. 2008..To describe HIV-1 variants circulating in Mali and to estimate the rate of transmission of HIV-1 drug resistance in 2006...
Rituximab therapy for HIV-associated Castleman diseaseAnne Genevieve Marcelin
Department of Virology, UPRES 2387, Pitie Salpetriere Hospital, Paris, France
Blood 102:2786-8. 2003..Our preliminary results suggest that rituximab may be effective in controlling Castleman disease in a subset of patients, although it may exacerbate concomitant Kaposi sarcoma...
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mlStéphanie Haïm-Boukobza
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris, Paris, France
AIDS 25:341-4. 2011..To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen...
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 49:1720-6. 2005..Therapeutic drug monitoring for patients treated by lopinavir-ritonavir would likely be most useful in patients with substantially resistant viruses...
Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapyAmelie Guihot
UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
AIDS 24:614-7. 2010..Long-term and efficient antiretroviral therapy provides continuous benefits both on the immune system and on the HIV reservoirs...
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapyAna Canestri
Hopital Pitie Salpetriere, Paris, France
Clin Infect Dis 50:773-8. 2010..We report data on 11 patients with neurological symptoms and human immunodeficiency virus (HIV) cerebrospinal fluid (CSF) viremia contrasting with suppressed plasma HIV RNA during receipt of combined antiretroviral therapy...
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavirLucile Larrouy
AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, 75018 Paris, France
Antimicrob Agents Chemother 55:1754-7. 2011..028). Our results suggest that a specific gag CSM might have a role on protease inhibitor susceptibility in an inhibitor-specific manner...
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide studyDominique Costagliola
INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
J Acquir Immune Defic Syndr 46:12-8. 2007..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patientsCathia Soulie
UMPC Université Paris 06, Paris, France
AIDS 22:2212-4. 2008..The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist...
High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV diseaseJean Gabarre
Service d Hematologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
Haematologica 89:1100-8. 2004....
Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infectionPhilippe Flandre
Unité INSERM U720, BP 335 75625, Paris, France
J Infect Dis 195:392-8. 2007..We investigated the relationship between human immunodeficiency virus (HIV) phenotypic susceptibility to didanosine and the antiviral activity of didanosine (ddI) in the JAGUAR study...
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in FranceDiane Descamps
Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
J Antimicrob Chemother 65:2620-7. 2010..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patientsAna Canestri
AP HP, Hopital Pitie Salpetriere, Service des Maladies Infectieuses et Tropicales, Paris, France
AIDS 24:2887-9. 2010..Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine...
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitutionMarc Wirden
Department of Virology, , Paris, France
AIDS 19:630-2. 2005..We found no clone bearing both K65R and L74V substitutions. Moreover, the S68G and V75I mutations are not necessarily linked with K65R, and could thus have their own resistance effect...
HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcomeNadia Prisant
UF de biologie de la reproduction, Groupe Hospitalier Pitie Salpetriere, 75013 Paris, France
Fertil Steril 93:1020-3. 2010..Clinical pregnancy rate for HIV-1 or HCV infertile serodiscordant couples was not significantly different from that for seronegative controls...
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1Yves Benhamou
Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
J Hepatol 44:62-7. 2006..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
Resistance to novel drug classesAnne Genevieve Marcelin
UMR INSERM UPMC, Université Pierre et Marie Curie U 943, AP HP, Hopital Pitie Salpetriere, Laboratoire de Virologie, Paris, France
Curr Opin HIV AIDS 4:531-7. 2009..Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread...
Effect of antiretroviral drugs on the quality of semenSidonie Lambert-Niclot
UPMC Pierre et Marie Curie University, Paris, France
J Med Virol 83:1391-4. 2011..NRTIs and PIs were not associated with any semen changes. Nevirapine was associated with a better quality of semen versus efavirenz. It would be of interest to validate, improve and test our penetration score in a prospective study...
Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipientsAnne Genevieve Marcelin
Department of Virology UPRES 2387, Pitie Salpetriere Hospital, Paris, France
Liver Transpl 10:295-300. 2004....
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patientsS Lambert-Niclot
INSERM U943, AP HP, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
HIV Med 11:666-9. 2010..The objective of this study was to explore the virological response when combination atazanavir/ritonavir was administered to treatment-naı¨ve patients...
Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kitC Deback
Service de Virologie du CERVI, UPRES EA 2387, Universite Pierre et Marie Curie Paris 6, Groupe Hospitalier Pitié Salpêtrière AP HP, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
J Virol Methods 149:285-91. 2008..7% (n=96) in A and B, respectively. These results demonstrate that the new commercial CMV HHV-6, 7, 8 R-gene kit was an efficient and reliable tool for the diagnosis of herpesvirus 6, 7, 8 infections...
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutationC Delaugerre
CHU Ambroise Pare, Boulogne, France
J Med Virol 80:762-5. 2008..In conclusion, the K70E mutation could be an alternative pathway of TDF resistance, but as the K65R mutation, other NRTI as ABC, ddI, and 3TC could be also associated with the K70E selection...
Comparison of two genotypic algorithms to determine HIV-1 tropismC Soulie
Department of Virology, Pitie Salpetriere Hospital, Pierre et Marie Curie Paris 6 University, 47 83 Bd de l Hopital, 75651 Paris Cedex 13, France
HIV Med 9:1-5. 2008..A comparison of the position-specific scoring matrices (PSSM) and Geno2pheno algorithms based on the V3 loop gp120 sequences and previously described to be correlated to the R5 or X4 phenotype was carried out...
The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survivalC Frances
Department of Dermatology Allergology, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Hopital Tenon, Paris, France
Am J Transplant 9:2580-6. 2009..In conclusion, although kidney recipients should be aware of the additional risk of KSHV morbidity, KSHV+ recipients should not be systematically excluded from kidney transplantation...
Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defectMarion Malphettes
Departement d Immunologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France
Clin Infect Dis 49:1329-38. 2009..Common variable immunodeficiency (CVID) is a primary immune deficiency defined by defective antibody production. In most series, a small proportion of patients present with opportunistic infections (OIs)...
Outcome of kidney transplant recipients with previous human herpesvirus-8 infectionC Frances
Department of Internal Medicine, Hopital Pitie Salpetriere, Paris, France
Transplantation 69:1776-9. 2000..The aim of this monocentric study was to determine the prevalence of HHV-8-seropositive patients at the time of transplantation and to identify the main clinical events of these HHV-8+ recipients...
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypesM Wirden
Department of Virology, Pitie Salpetriere Hospital, Paris, France
J Clin Microbiol 47:1543-5. 2009..The differences exceeded 0.5 log for about 20% of samples and 1 log for 3%, with higher values always from the Abbott assay in the latter cases...
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapyP Bossi
Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
HIV Med 5:352-9. 2004..To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy in multiexperienced patients infected with HIV-1...
KSHV after an organ transplant: should we screen?A G Marcelin
Department of Virology, Pitie Salpetriere Hospital, Pierre et Marie Curie University, UPRES EA 2387, 83 bd de l hopital, 75013 Paris, France
Curr Top Microbiol Immunol 312:245-62. 2007....
Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipientsS Barete
Service de Virologie CERVI, Groupe Hospitalier Pitie Salpetriere, 83, Boulevard de l Hôpital 75651, Paris, Cedex 13, France
Arch Dermatol 136:1452-8. 2000..To describe the clinical features of Kaposi sarcoma (KS) in organ-allograft recipients and to determine the contribution of human herpesvirus 8 (HHV-8) investigations to the management of KS...
Stability of HIV RNA in plasma specimens stored at different temperaturesB Amellal
Department of Virology, Pitie Salpetriere Hospital, Paris, France
HIV Med 9:790-3. 2008..Samples from remote areas are transported under suboptimal conditions. Here we evaluated HIV-1 RNA stability in plasma stored at different temperatures for 1 week...
[Primary effusion lymphoma in two kidney transplant recipients]E Régnier-Rosencher
Service de Dermatologie, Hopital Tenon, AP HP, 4, rue de la Chine, 75020 Paris, France
Ann Dermatol Venereol 137:285-9. 2010..It is chiefly seen in HIV patients and is rare in transplant recipients, possibly going unrecognized...
Effects of cyclosporine and hydrocortisone on Kaposi's sarcoma-associated herpesvirus genome replication and cell apoptosis inductionA G Marcelin
Department of Virology, CERVI, , AP-HP, , 75013 Paris, France
Transplantation 72:1700-3. 2001..1 expression. CONCLUSION: Our results suggest that immunosuppressive agents such as HC and CsA do not activate the lytic cycle of KSHV and do not modify the cell survival thus promoting cancer progression by a direct cellular effect...
